Disrupting MALAT1/miR-200c sponge decreases invasion and migration in endometrioid endometrial carcinoma

Cancer Letters

Volumn 383, Issue 1, 2016, Pages 28-40

  Li, Qiulian ^a,c   Zhang, Chao ^b   Chen, Ruichao ^a   Xiong, Hanzhen ^a   Qiu, Fuman ^a   Liu, Shaoyan ^a   Zhang, Minfen ^a   Wang, Fang ^a   Wang, Yu ^b   Zhou, Xuan ^b   Xiao, Guohong ^a   Wang, Xudong ^b   Jiang, Qingping ^a  

^a GUANGZHOU MEDICAL UNIVERSITY   (China)

^b TIANJIN MEDICAL UNIVERSITY   (China)

^c GANNAN MEDICAL UNIVERSITY   (China)

Author keywords

Endometrioid endometrial carcinoma; Invasion; MALAT1; miR 200c

Indexed keywords

LONG UNTRANSLATED RNA; METASTASIS ASSOCIATED LUNG ADENOCARCINOMA TRANSCRIPT 1; MICRORNA 200C; ONCOPROTEIN; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; 3' UNTRANSLATED REGION; MALAT1 LONG NON-CODING RNA, HUMAN; MICRORNA; MIRN200 MICRORNA, HUMAN; TUMOR MARKER;

3' UNTRANSLATED REGION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BINDING AFFINITY; CELL CYCLE ASSAY; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; ENDOMETRIOID CARCINOMA; ENDOMETRIUM CARCINOMA; EPITHELIAL MESENCHYMAL TRANSITION; FEMALE; GENE FUNCTION; GENE INTERACTION; GENE TARGETING; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOFLUORESCENCE; MOUSE; NONHUMAN; ONCOLOGICAL PARAMETERS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INTERACTION; PROTEIN TARGETING; QUANTITATIVE ANALYSIS; REGULATORY MECHANISM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR INVASION; WESTERN BLOTTING; ANIMAL; BAGG ALBINO MOUSE; BINDING SITE; CELL MOTION; DRUG EFFECTS; ENDOMETRIUM TUMOR; GENE EXPRESSION REGULATION; GENETIC TRANSFECTION; GENETICS; METABOLISM; NUDE MOUSE; PATHOLOGY; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TIME FACTOR; TUMOR CELL LINE; TUMOR VOLUME;

3' UNTRANSLATED REGIONS; ANIMALS; BINDING SITES; BIOMARKERS, TUMOR; CARCINOMA, ENDOMETRIOID; CELL LINE, TUMOR; CELL MOVEMENT; ENDOMETRIAL NEOPLASMS; EPITHELIAL-MESENCHYMAL TRANSITION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICE, INBRED BALB C; MICE, NUDE; MICRORNAS; NEOPLASM INVASIVENESS; RNA INTERFERENCE; RNA, LONG NONCODING; SIGNAL TRANSDUCTION; TIME FACTORS; TRANSFECTION; TRANSFORMING GROWTH FACTOR BETA; TUMOR BURDEN;

EID: 85007574205     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2016.09.019     Document Type: Article

References (45)

1. [1] Siegel, R., Naishadham, D., Jemal, A., Cancer statistics, 2013. CA Cancer J. Clin 63:1 (2013), 11–30.
2. [2] Yang, L., Parkin, D.M., Whelan, S., Zhang, S., Chen, Y., Lu, F., et al. Statistics on cancer in China: cancer registration in 2002. Eur. J. Cancer Prev. 14:4 (2005), 329–335.
3. [3] Snowdon, J., Zhang, X., Childs, T., Tron, V.A., Feilotter, H., The microRNA-200 family is upregulated in endometrial carcinoma. PLoS One, 6(8), 2011 e22828.
4. [4] Wu, W., Lin, Z., Zhuang, Z., Liang, X., Expression profile of mammalian microRNAs in endometrioid adenocarcinoma. Eur. J. Cancer Prev. 18:1 (2009), 50–55.
5. [5] Xiong, H., Li, Q., Liu, S., Wang, F., Xiong, Z., Chen, J., et al. Integrated microRNA and mRNA transcriptome sequencing reveals the potential roles of miRNAs in stage I endometrioid endometrial carcinoma. PLoS One, 9(10), 2014 e110163.
6. [6] Park, S.M., Gaur, A.B., Lengyel, E., Peter, M.E., The miR-200 family determines the epithelial phenotype of cancer cells by targeting the E-cadherin repressors ZEB1 and ZEB2. Genes Dev. 22:7 (2008), 894–907.
7. [7] Korpal, M., Kang, Y., The emerging role of miR-200 family of microRNAs in epithelial-mesenchymal transition and cancer metastasis. RNA Biol. 5:3 (2008), 115–119.
8. [8] Gregory, P.A., Bracken, C.P., Bert, A.G., Goodall, G.J., MicroRNAs as regulators of epithelial-mesenchymal transition. Cell Cycle 7:20 (2008), 3112–3118.
9. [9] Lee, J.W., Park, Y.A., Choi, J.J., Lee, Y.Y., Kim, C.J., Choi, C., et al. The expression of the miRNA-200 family in endometrial endometrioid carcinoma. Gynecol. Oncol. 120:1 (2011), 56–62.
10. [10] Elson-Schwab, I., Lorentzen, A., Marshall, C.J., MicroRNA-200 family members differentially regulate morphological plasticity and mode of melanoma cell invasion. PLoS One, 5(10), 2010 e13176.
11. [11] Iorio, M.V., Visone, R., Di Leva, G., Donati, V., Petrocca, F., Casalini, P., et al. MicroRNA signatures in human ovarian cancer. Cancer Res. 67:18 (2007), 8699–8707.
12. [12] Xi, Y., Formentini, A., Chien, M., et al. Prognostic values of microRNAs in colorectal cancer. Biomark. Insights 2 (2006), 113–121.
13. [13] Cochrane, D.R., Cittelly, D.M., Richer, J.K., Steroid receptors and microRNAs: relationships revealed. Steroids 76:1–2 (2011), 1–10.
14. [14] Qiao, H.P., Gao, W.S., Huo, J.X., Yang, Z.S., Long non-coding RNA GAS5 functions as a tumor suppressor in renal cell carcinoma. Asian Pac. J. Cancer 14 (2013), 1077–1082.
15. [15] Bertozzi, D., Iurlaro, R., Sordet, O., Marinello, J., Zaffaroni, N., Capranico, G., Characterization of novel antisense HIF-1 alpha transcripts in human cancers. Cell Cycle 10:18 (2011), 3189–3197.
16. [16] Gupta, R.A., Shah, N., Wang, K.C., Kim, J., Horlings, H.M., Wong, D.J., et al. Long non-coding RNA HOTAIR reprograms chromatin state to promote cancer metastasis. Nature 464:7291 (2010), 1071–1076.
17. [17] Ji, P., Diederichs, S., Wang, W., Boing, S., Metzger, R., Schneider, P.M., et al. MALAT-1, a novel noncoding RNA, and thymosin beta4 predict metastasis and survival in early-stage non-small cell lung cancer. Oncogene 22:39 (2003), 8031–8041.
18. [18] Shi, X., Sun, M., Liu, H., Yao, Y., Song, Y., Long non-coding RNAs: a new frontier in the study of human diseases. Cancer Lett. 339:2 (2013), 159–166.
19. [19] Tripathi, V., Shen, Z., Chakraborty, A., Giri, S., Freier, S.M., Wu, X., et al. Long noncoding RNA MALAT1 controls cell cycle progression by regulating the expression of oncogenic transcription factor B-MYB. PLoS Genet., 9(3), 2013 e1003368.
20. [20] Gutschner, T., Hammerle, M., Eissmann, M., Hsu, J., Kim, Y., Hung, G., et al. The noncoding RNA MALAT1 is a critical regulator of the metastasis phenotype of lung cancer cells. Cancer Res. 73:3 (2013), 1180–1189.
21. [21] Zhao, Y., Yang, Y., Trovik, J., Sun, K., Zhou, L., Jiang, P., et al. A novel wnt regulatory axis in endometrioid endometrial cancer. Cancer Res. 74:18 (2014), 5103–5117.
22. [22] Ying, L., Chen, Q., Wang, Y., Zhou, Z., Huang, Y., Qiu, F., Upregulated MALAT-1 contributes to bladder cancer cell migration by inducing epithelial-to-mesenchymal transition. Mol. Biosyst. 8:9 (2012), 2289–2294.
23. [23] Klymkowsky, M.W., Savagner, P., Epithelial-mesenchymal transition: a cancer researcher's conceptual friend and foe. Am. J. Pathol 174:5 (2009), 1588–1593.
24. [24] Burk, U., Schubert, J., Wellner, U., Schmalhofer, O., Vincan, E., Spaderna, S., et al. A reciprocal repression between ZEB1 and members of the miR-200 family promotes EMT and invasion in cancer cells. EMBO Rep. 9:6 (2008), 582–589.
25. [25] Gregory, P.A., Bert, A.G., Paterson, E.L., Barry, S.C., Tsykin, A., Farshid, G., et al. The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. Nat. Cell Biol. 10:5 (2008), 593–601.
26. [26] Yuan, J.H., Yang, F., Wang, F., Ma, J.Z., Guo, Y.J., Tao, Q.F., et al. A long noncoding RNA activated by TGF-beta promotes the invasion-metastasis cascade in hepatocellular carcinoma. Cancer Cell 25:5 (2014), 666–681.
27. [27] Fan, Y., Shen, B., Tan, M., Mu, X., Qin, Y., Zhang, F., et al. TGF-beta-induced upregulation of malat1 promotes bladder cancer metastasis by associating with suz12. Clin. Cancer Res. 20:6 (2014), 1531–1541.
28. [28] Hirata, H., Hinoda, Y., Shahryari, V., Deng, G., Nakajima, K., Tabatabai, Z.L., et al. Long noncoding RNA MALAT1 promotes aggressive renal cell carcinoma through Ezh2 and interacts with miR-205. Cancer Res. 75:7 (2015), 1322–1331.
29. [29] Li, S., Wang, Q., Qiang, Q., Shan, H., Shi, M., Chen, B., et al. Sp1-mediated transcriptional regulation of MALAT1 plays a critical role in tumor. J. Cancer Res. Clin. Oncol 141 (2015), 1909–1920.
30. [30] Tripathi, V., Ellis, J.D., Shen, Z., Song, D.Y., Pan, Q., Watt, A.T., et al. The nuclear-retained noncoding RNA MALAT1 regulates alternative splicing by modulating SR splicing factor phosphorylation. Mol. Cell 39:6 (2010), 925–938.
31. [31] Zhou, X., Liu, S., Cai, G., Kong, L., Zhang, T., Ren, Y., et al. Long non coding RNA MALAT1 promotes tumor growth and metastasis by inducing epithelial-mesenchymal transition in oral squamous cell carcinoma. Sci. Rep., 5, 2015, 15972.
32. [32] Ren, S., Liu, Y., Xu, W., Sun, Y., Lu, J., Wang, F., et al. Long noncoding RNA MALAT-1 is a new potential therapeutic target for castration resistant prostate cancer. J. Urol. 190:6 (2013), 2278–2287.
33. [33] Lai, M.C., Yang, Z., Zhou, L., Zhu, Q.Q., Xie, H.Y., Zhang, F., et al. Long non-coding RNA MALAT-1 overexpression predicts tumor recurrence of hepatocellular carcinoma after liver transplantation. Med. Oncol. 29:3 (2012), 1810–1816.
34. [34] Xu, C., Yang, M., Tian, J., Wang, X., Li, Z., MALAT-1: a long non-coding RNA and its important 3' end functional motif in colorectal cancer metastasis. Int. J. Oncol. 39:1 (2011), 169–175.
35. [35] Wang, P., Liu, Y.H., Yao, Y.L., Li, Z., Li, Z.Q., Ma, J., et al. Long non-coding RNA CASC2 suppresses malignancy in human gliomas by miR-21. Cell. Signal. 27:2 (2015), 275–282.
36. [36] Zhang, Z., Zhu, Z., Watabe, K., Zhang, X., Bai, C., Xu, M., et al. Negative regulation of lncRNA GAS5 by miR-21. Cell Death Differ. 20:11 (2013), 1558–1568.
37. [37] Han, X., Yang, F., Cao, H., Liang, Z., Malat1 regulates serum response factor through miR-133 as a competing endogenous RNA in myogenesis. FASEB J. 29:7 (2015), 3054–3064.
38. [38] Leucci, E., Patella, F., Waage, J., Holmstrom, K., Lindow, M., Porse, B., et al. Microrna-9 targets the long non-coding RNA MALAT1 for degradation in the nucleus. Sci. Rep., 3, 2013, 2535.
39. [39] Han, Y., Liu, Y., Zhang, H., Wang, T., Diao, R., Jiang, Z., et al. Hsa-miR-125b suppresses bladder cancer development by down-regulating oncogene SIRT7 and oncogenic long non-coding RNA MALAT1. FEBS Lett. 587:23 (2013), 3875–3882.
40. [40] Wang, X., Li, M., Wang, Z., Han, S., Tang, X., Ge, Y., et al. Silencing of long noncoding RNA MALAT1 by miR-101 and miR-217 inhibits proliferation, migration, and invasion of esophageal squamous cell carcinoma cells. J. Biol. Chem. 290:7 (2015), 3925–3935.
41. [41] Bai, W.D., Ye, X.M., Zhang, M.Y., Zhu, H.Y., Xi, W.J., Huang, X., et al. miR-200c suppresses TGF-beta signaling and counteracts trastuzumab resistance and metastasis by targeting ZNF217 and ZEB1 in breast cancer. Int. J. Cancer 135:6 (2014), 1356–1368.
42. [42] Wang, X., Chen, X., Han, W., Ruan, A., Chen, L., Wang, R., et al. miR-200c targets CDK2 and suppresses tumorigenesis in renal cell carcinoma. Mol. Cancer Res. 13 (2015), 1567–1577.
43. [43] Ma, M.Z., Chu, B.F., Zhang, Y., Weng, M.Z., Qin, Y.Y., Gong, W., et al. Long non-coding RNA CCAT1 promotes gallbladder cancer development via negative modulation of miRNA-218-5p. Cell Death Dis, 6, 2015 e1583.
44. [44] Dey, B.K., Pfeifer, K., Dutta, A., The H19 long noncoding RNA gives rise to microRNAs miR-675-3p and miR-675-5p to promote skeletal muscle differentiation and regeneration, Genes Dev. 28:5 (2014), 491–501.
45. [45] Xiao, H., Tang, K., Liu, P., Chen, K., Hu, J., Zeng, J., et al. LncRNA MALAT1 functions as a competing endogenous RNA to regulate ZEB2 expression by sponging miR-200s in clear cell kidney carcinoma. Oncotarget 6:35 (2015), 38005–38015.